Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary efficacy objective of this study is to evaluate the effect of RO4607381 on endothelial function as measured by flow mediated dilatation (FMD) of the brachial artery in patients with CHD or CHD risk equivalents at 12 weeks. The primary safety objective of this study is to evaluate the effect of RO4607381 on blood pressure as measured by 24 hour ambulatory blood pressure monitoring (ABPM) at 4 weeks.
Critère d'inclusion
- Patients with Coronary Heart Disease (CHD) or CHD Risk Equivalents